Ivantis takes its Series B round to $71 million with another $25 million tranche as it looks to get its Hydrus micro-stent for glaucoma on the U.S. market.
Ivantis today said it added a $25 million tranche to its now $71 million Series B round as the Irvine, Calif.-based company looks to bring its miniature glaucoma scaffold to the U.S. market.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1v5r2oF
Cap comentari:
Publica un comentari a l'entrada